{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:44:20Z","timestamp":1793252660984,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jinf.2025.106582","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:57:16Z","timestamp":1754582236000},"page":"106582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The United Kingdom meningococcal vaccine (4CMenB) programme against gonorrhoea: A review of the evidence and knowledge gaps"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-2476","authenticated-orcid":false,"given":"Shamez N.","family":"Ladhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Fifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2025.106582_bib1","series-title":"Guidance. Introduction of new routine mpox and 4CMenB for gonorrhoea vaccination programmes letter","author":"UK Health Security Agency (UKHSA)","year":"2025"},{"key":"10.1016\/j.jinf.2025.106582_bib2","series-title":"Guidance. Gonorrhoea: the green book chapter. Gonorrhoea immunisation information for public health professionals","author":"UK Health Security Agency (UKHSA)","year":"2025"},{"issue":"7","key":"10.1016\/j.jinf.2025.106582_bib3","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S1473-3099(21)00744-1","article-title":"Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis","volume":"22","author":"Whittles","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2025.106582_bib4","unstructured":"Rogers A. British Broadcasting Corporation (BBC) Online. Newsbeat: Doctors and charities call for gonorrhoea vaccine roll-out. \u3008https:\/\/www.bbc.co.uk\/news\/articles\/cly3el161k3o\u3009. [Accessed 15 July 2025]."},{"issue":"1","key":"10.1016\/j.jinf.2025.106582_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"10.1016\/j.jinf.2025.106582_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0956462419886775","article-title":"2018 UK national guideline for the management of infection with Neisseria gonorrhoeae","volume":"31","author":"Fifer","year":"2020","journal-title":"Int J STD AIDS"},{"issue":"5","key":"10.1016\/j.jinf.2025.106582_bib7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/jac\/dkaf109","article-title":"The continuing evolution of antibiotic resistance in Neisseria gonorrhoeae: past, present and future threats to effective treatment","volume":"80","author":"Fifer","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2025.106582_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/09564624251345195","article-title":"British Association of Sexual Health and HIV UK national guideline for the management of infection with Neisseria gonorrhoeae, 2025","author":"Fifer","year":"2025","journal-title":"Int J STD AIDS"},{"issue":"6","key":"10.1016\/j.jinf.2025.106582_bib9","first-page":"454","article-title":"Effectiveness of condoms in preventing sexually transmitted infections","volume":"82","author":"Holmes","year":"2004","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jinf.2025.106582_bib10","series-title":"Gonorrhoea (Neisseria gonorrhoeae infection)","author":"World Health Organization (WHO)","year":"2024"},{"key":"10.1016\/j.jinf.2025.106582_bib11","series-title":"Official statistics. Sexually transmitted infections and screening for chlamydia in England: 2024 report","author":"UK Health Security Agency (UKHSA)","year":"2025"},{"issue":"8","key":"10.1016\/j.jinf.2025.106582_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1177\/09564624251333489","article-title":"A global meta-analysis of gonorrhoea and chlamydia prevalence among men who have sex with men from 2000 to 2022","volume":"36","author":"Davies","year":"2025","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jinf.2025.106582_bib13","series-title":"Global HIV, hepatitis and STIs programmes. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030","author":"World Health Organization (WHO)","year":"2022"},{"issue":"1","key":"10.1016\/j.jinf.2025.106582_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00094-23","article-title":"Neisseria gonorrhoeae vaccines: a contemporary overview","volume":"37","author":"Williams","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2025.106582_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1119834","article-title":"Mechanisms of host manipulation by Neisseria gonorrhoeae","volume":"14","author":"Walker","year":"2023","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.jinf.2025.106582_bib16","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S1473-3099(24)00031-8","article-title":"Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK","volume":"24","author":"Ladhani","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"10102","key":"10.1016\/j.jinf.2025.106582_bib17","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jinf.2025.106582_bib18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/14760584.2023.2222015","article-title":"A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)","volume":"22","author":"Marshall","year":"2023","journal-title":"Expert Rev Vaccin"},{"issue":"7","key":"10.1016\/j.jinf.2025.106582_bib19","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","article-title":"First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: prospective enhanced national surveillance, England","volume":"73","author":"Ladhani","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2025.106582_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with meningococcal group B vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jinf.2025.106582_bib21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2025.106582_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41541-024-01018-4","article-title":"NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae","volume":"9","author":"Tzeng","year":"2024","journal-title":"NPJ Vaccin"},{"issue":"6","key":"10.1016\/j.jinf.2025.106582_bib23","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/OLQ.0000000000001793","article-title":"Healthy vaccinee bias and MenB-FHbp vaccine effectiveness against gonorrhea","volume":"50","author":"Abara","year":"2023","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.jinf.2025.106582_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106225","article-title":"Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: a systematic review and meta-analysis","volume":"89","author":"Wang","year":"2024","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jinf.2025.106582_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae726","article-title":"Long-term 4CMenB vaccine effectiveness against gonococcal infection at four years post-program implementation: observational case-control study","volume":"12","author":"Wang","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jinf.2025.106582_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf372","article-title":"Long-term protection against invasive meningococcal B disease and gonococcal infection five years after implementation of funded childhood and adolescent 4CMenB vaccination program in South Australia: an observational cohort and case-control study","author":"Wang","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2025.106582_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1473-3099(24)00236-6","article-title":"Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2\u00d72 factorial design","volume":"24","author":"Molina","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2025.106582_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00452-3","article-title":"The potential role of the 4CMenB vaccine in combating gonorrhoea: the need for nuance in interpreting the DOXYVAC trial","volume":"24","author":"White","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2025.106582_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/infdis\/jiae123","article-title":"Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection","volume":"231","author":"Nikitin","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2025.106582_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/813789","article-title":"Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis","volume":"2014","author":"Edlefsen","year":"2014","journal-title":"Comput Math Methods Med"},{"issue":"11","key":"10.1016\/j.jinf.2025.106582_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae562","article-title":"Breakthrough rectal neisseria gonorrhoeae infections after meningococcal B vaccination: microbiological and clinical features","volume":"11","author":"Raccagni","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jinf.2025.106582_bib32","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3389\/fimmu.2019.02417","article-title":"Progress toward a gonococcal vaccine: the way forward","volume":"10","author":"Russell","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2025.106582_bib33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-micro-090816-093530","article-title":"Neisseria gonorrhoeae: drug resistance, mouse models, and vaccine development","volume":"71","author":"Rice","year":"2017","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.jinf.2025.106582_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-1-0716-1900-1_19","article-title":"Assessment of serum bactericidal and opsonophagocytic activity of antibodies to gonococcal vaccine targets","volume":"2414","author":"Semchenko","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"12","key":"10.1016\/j.jinf.2025.106582_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00309-23","article-title":"Evaluating vaccine-elicited antibody activities against Neisseria gonorrhoeae: cross-protective responses elicited by the 4CMenB meningococcal vaccine","volume":"91","author":"Gray","year":"2023","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2025.106582_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/09564624251352053","article-title":"British Association for Sexual Health and HIV (BASHH) UK national guideline for the use of doxycycline post-exposure prophylaxis (DoxyPEP) for the prevention of syphilis, 2025","author":"Saunders","year":"2025","journal-title":"Int J STD AIDS"},{"issue":"12","key":"10.1016\/j.jinf.2025.106582_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003807","article-title":"Knowledge, uptake and intention to use antibiotic post-exposure prophylaxis and meningococcal B vaccine (4CMenB) for gonorrhoea among a large, online community sample of men and gender-diverse individuals who have sex with men in the UK","volume":"4","author":"Ogaz","year":"2024","journal-title":"PLOS Glob Public Health"},{"issue":"5","key":"10.1016\/j.jinf.2025.106582_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf214","article-title":"New insights into gonorrhea natural history and protection by 4CMenB, and a call for more analyses of existing studies and enhanced data collection","volume":"12","author":"White","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jinf.2025.106582_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127180","article-title":"Cross-protection of meningococcal B vaccines against gonorrhea: a systematic review and Meta-analysis","volume":"56","author":"Georgiadis","year":"2025","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.jinf.2025.106582_bib40","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S1473-3099(24)00001-X","article-title":"Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions","volume":"24","author":"Allan-Blitz","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2025.106582_bib41","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1473-3099(22)00343-7","article-title":"We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site","volume":"22","author":"White","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.jinf.2025.106582_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008602","article-title":"The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae","volume":"16","author":"Leduc","year":"2020","journal-title":"PLoS Pathog"},{"issue":"4","key":"10.1016\/j.jinf.2025.106582_bib43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jinf.2025.106582_bib44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.7774\/cevr.2019.8.2.110","article-title":"A meningococcal B vaccine induces cross-protection against gonorrhea","volume":"8","author":"Azze","year":"2019","journal-title":"Clin Exp Vaccin Res"},{"key":"10.1016\/j.jinf.2025.106582_bib45","series-title":"BASHH summary guidance on testing for sexually transmitted infections","author":"British Association for Sexual Health and HIV (BASHH)","year":"2023"},{"issue":"4","key":"10.1016\/j.jinf.2025.106582_bib46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(18)30048-3","article-title":"Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis","volume":"18","author":"Flacco","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"38","key":"10.1016\/j.jinf.2025.106582_bib47","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.15585\/mmwr.mm6738a4","article-title":"Meningococcal disease surveillance in men who have sex with men - United States, 2015-2016","volume":"67","author":"Bozio","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.jinf.2025.106582_bib48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/sextrans-2024-056269","article-title":"Invasive Neisseria meningitidis subtype C in gay, bisexual and other men who have sex with men: a systematic review","volume":"101","author":"Rabuszko","year":"2025","journal-title":"Sex Transm Infect"},{"issue":"5","key":"10.1016\/j.jinf.2025.106582_bib49","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/cid\/cix438","article-title":"Increased risk for meningococcal disease among men who have sex with men in the United States, 2012-2015","volume":"65","author":"Folaranmi","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10240","key":"10.1016\/j.jinf.2025.106582_bib50","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0140-6736(20)30913-2","article-title":"Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidis","volume":"395","author":"Ladhani","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jinf.2025.106582_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243426","article-title":"Genomic analysis of the meningococcal ST-4821 complex-Western clade, potential sexual transmission and predicted antibiotic susceptibility and vaccine coverage","volume":"15","author":"Lucidarme","year":"2020","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.jinf.2025.106582_bib52","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.15.2000375","article-title":"Detection of the United States Neisseria meningitidis urethritis clade in the United Kingdom, August and December 2019 - emergence of multiple antibiotic resistance calls for vigilance","volume":"25","author":"Brooks","year":"2020","journal-title":"Eur Surveill"},{"issue":"12","key":"10.1016\/j.jinf.2025.106582_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00462-20","article-title":"Neisseria meningitidis urethritis outbreak isolates express a novel factor h binding protein variant that is a potential target of group B-directed meningococcal (MenB) vaccines","volume":"88","author":"Tzeng","year":"2020","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2025.106582_bib54","author":"G\u00fcell","year":"2025","journal-title":"Soc El Pa\u00eds"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325001823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325001823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:11:24Z","timestamp":1772788284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325001823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0163445325001823"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106582","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The United Kingdom meningococcal vaccine (4CMenB) programme against gonorrhoea: A review of the evidence and knowledge gaps","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106582"}}